Six1 gene promoter’s methylation in gastric cancer and its value for evaluating the disease condition and prognosis
KONG Fan-jing*, YU Hong-gang,ZHOU Zhong-yin,CAO Ji-wang,Chen Ming-kai
*Department of Gastroenterology, the People’s Hospital of Wuhan University, Wuhan, Hubei 430060, China Corresponding author: Chen Ming-kai,E-mail:kaimingchen@163.com
Abstract：Objective To detect Six1 gene promoter’s hypomethylation in patients with gastric cancer and study its clinical value in assessing the disease condition and prognosis. Methods Methylation specific PCR (MSP) was used to detect the methylation of Six1 gene promoter in gastric cancer tissue (gastric cancer group) and in gastric tissue of gastritis patients (the control group), and the detection results were compared between the two groups. The relationship between clinicopathological factors and Six1 gene promoter’s methylation was analyzed. The differences of surgical result, 3-year mortality and progression-free survival (PFS) between patients with Six1 gene promoter methylation and unmethylation in the gastric cancer group were compared. Results The methylation rate of Six1 gene promoter in the tumor tissues of the gastric cancer group was significantly lower than that in the gastric tissues of thecontrol group (24.0% vs. 95.0%, P<0.05). The prevalence of Six1 gene promoter’s methylation in the gastric cancer group differred significantly in tumors with different Lauren’s typing, histology differentiation, maximum tumor diameters, lymph node metastasis, distant metastasis and TNM staging (all P<0.05). The D2 radical operation rate, negative rate of surgical margin and PFS time in patients with Six1 gene promoter methylation were significantly higher than those in patients without Six1 gene promoter methylation (100.0% vs. 57.9%, 100.0% vs. 47.4%, (23.6±3.5) months vs. (13.2±2.7) months, all P<0.05), while the 3-year mortality rate was significantly lower (P<0.05). Conclusions: Six1 gene promoter is hypomethylated in patients with gastric cancer, and it can serve as a tumor biomarker in disease condition and prognosis assessment.
孔繁静,于红刚,周中银,操寄望,陈明锴. 胃癌Six1基因启动子甲基化及其在病情及预后评估中的价值[J]. 实用预防医学, 2017, 24(4): 404-406.
KONG Fan-jing, YU Hong-gang,ZHOU Zhong-yin,CAO Ji-wang,Chen Ming-kai. Six1 gene promoter’s methylation in gastric cancer and its value for evaluating the disease condition and prognosis. , 2017, 24(4): 404-406.
[1] 金爱花,金海燕.Six1蛋白在恶性肿瘤中的研究进展[J].临床与实验病理学杂志,2014,30(4):437-439,440. [2] 马小斌,宋雅璠,陈洪志,等.乳腺癌患者血清中Six1的检测及临床意义[J].现代肿瘤医学,2015,23(17):2450-2452. [3] 朱鹏武,吴春松,郑海红,等.大肠癌组织中Six1和CyclinD1的表达及其临床意义[J].浙江临床医学,2015,17(11):1868-1869,1886. [4] 魏巧,郁玮玮,赵快乐,等.Six1和Six4在食管鳞状细胞癌组织中的表达及其与预后的关系[J].中华病理学杂志,2013,42(7):446-450. [5] 杨明昊,谢莎,谢小薰,等.胶质瘤CpG岛甲基化表型的研究进展[J].中华神经外科杂志,2015,31(5):530-532. [6] 贺娜,吴开春.血浆甲基化septin9基因与结直肠癌相关性的研究进展[J].中华消化杂志,2015,35(5):358-360. [7] 王凤,王睿,王衍晶,等.DNA启动子甲基化致ADAMTS9蛋白下调促进大肠癌病程进展[J].中国癌症杂志,2015,25(6):445-450. [8] Wu W, Ren Z, Liu H, et al.Core promoter analysis of porcine Six1 gene and its regulation of the promoter activity by CpG methylation[J].Gene,2013,529(2):238-244. [9] Nagel S, Meyer C, Kaufmann M, et al.Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma[J].Oncotarget,2015,6(37):40112-40126. [10] Zeng J, Shi R, Cai CX, et al.Increased expression of Six1 correlates with progression and prognosis of prostate cancer[J].Cancer Cell Int,2015,15:63.
2017, Vol. 24 
